NEW YORK, July 29, 2019 /PRNewswire/ -- WeissLaw
LLP is investigating possible breaches of fiduciary duty
and other violations of law by the Board of Directors of Genomic
Health, Inc. ("Genomic Health" or the "Company") (NASDAQ: GHDX) in
connection with the proposed acquisition of the Company by Exact
Science Corp. ("EXAS") (NASDAQ: EXAS). Under the terms of the
agreement, Genomic Health shareholders will receive $27.50 in cash and $44.50 in EXAS shares for each GHDX share held,
representing consideration of $72.00
per GHDX share.
If you own Genomic Health shares and wish to
discuss this investigation or have any questions concerning this
notice or your rights or interests, please contact:
Joshua Rubin,
Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888)
593-4771
stockinfo@weisslawllp.com
Visit our
website
http://www.weisslawllp.com/genomic-health-inc/
Or follow us on Twitter @MarketsAlert
WeissLaw is investigating whether Genomic Health's Board acted
to maximize shareholder value prior to entering into the
acquisition agreement. Notably, at least one analyst set a
target price of $77.00, or
$5.00 above the per-share
consideration. Additionally, according to the acquisition
announcement, the deal will propel EXAS as a global leader in the
industry, forming a "best-in-class commercial research, development
and clinical organization, with enhanced scale and scope in cancer
diagnostic." Moreover, the Company recently announced revenue
of $114.1 million in the second
quarter of 2019, representing an impressive 19.4% year-over-year
growth when compared to the figures reported for the same quarter
of the previous year.
Finally, upon completion of the transaction, EXAS shareholders
will own 91% of the combined company, leaving a meager 9% for GHDX
and its shareholders.
WeissLaw is investigating whether Genomic Health's Board
conducted a fair process in agreeing to the proposed acquisition,
whether the proposed acquisition undervalues the Company, and
whether all material information related to the proposed
acquisition is fully and fairly disclosed.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-genomic-health-inc-300892684.html
SOURCE WeissLaw LLP
